Elevated serum level and gene polymorphisms of TGF-β1 in gastric cancer

✍ Scribed by Xue Li; Zhi-Chao Yue; Yun-Yan Zhang; Jing Bai; Xiang-ning Meng; Jing-Shu Geng; Song-Bin Fu

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 227 KB
• Volume: 22
• Category: Article
• ISSN: 0887-8013
• DOI: 10.1002/jcla.20236

✦ Synopsis

Abstract

Transforming growth factor (TGF)‐β1, as a candidate tumor marker, is currently of interest. In this study, serum TGF‐β1 levels in gastric cancer (GC) patients and healthy volunteers were measured using enzyme‐linked immunosorbent assay (ELISA). In addition, single nucleotide polymorphisms (SNPs) of the TGF‐β1 gene at codon 10 and codon 25 were identified by means of amplification refractory mutation system–polymerase chain reaction (ARMS‐PCR) and sequence analysis. Our results indicated that serum concentrations of TGF‐β1 in GC patients were significantly higher than those in the control, and positively correlated with tumor mass, invasion, metastasis, and clinical stage. The serum TGF‐β1 levels of patients recovering from radical resection were markedly lower than those before surgery. Meanwhile, no deoxyribonucleic acid (DNA) sequence variation at codon 25 of the TGF‐β1 gene was found and a TGF‐β1 gene polymorphism at codon 10 did not show obvious correlations with either TGF‐β1 expression or clinicopathological parameters of GC. Our evidence suggested that serum concentration of TGF‐β1 might be a novel tumor marker for GC and the polymorphisms of TGF‐β1 gene did not play a role as a determinant of serum TGF‐β1 concentration or as a genetic risk factor in the gastric carcinogenesis and progression. J. Clin. Lab. Anal. 22:164–171, 2008. © 2008 Wiley‐Liss, Inc.